Navigation Links
Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
Date:8/7/2008

s and patent infringement cases; the outcome of litigation arising from challenging the validity or non- infringement of patents covering our products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; the ability of competitors to extend exclusivity periods for their products; our ability to complete product development activities in the timeframes and for the costs we expect; market and customer acceptance and demand for our pharmaceutical products; our dependence on revenues from significant customers; reimbursement policies of third party payors; our dependence on revenues from significant products; the use of estimates in the preparation of our financial statements and our forecasts; the impact of competitive products and pricing on products, including the launch of authorized generics; the ability to launch new products in the timeframes we expect; the availability of raw materials; the availability of any product we purchase and sell as a distributor; the regulatory environment in the markets where we operate; our exposure to product liability and other lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies (such as PLIVA d.d.) and products we acquire and implementing our new SAP enterprise resource planning system; fluctuations in operating results, including the effects on such results from spending for research and development, sales and marketing activities and patent challenge activities; the inherent uncertainty associated with financial projections; our expansion into international markets through our PLIVA acquisition, and the resulting currency, governmental, regulatory and other risks involved with international operations; our ability to service our significantly increased debt obligations as a result of the PLIVA acquisition; change
'/>"/>
SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
2. Caliper Life Sciences Reports Second Quarter 2008 Results
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. EntreMed Reports Second Quarter 2008 Financial Results
5. Transgenomic Reports Second Quarter 2008 Results
6. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
7. Bionovo Reports Second Quarter 2008 Financial Results
8. AtriCure Reports Record Second Quarter 2008 Financial Results
9. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
10. eResearchTechnology Reports Second Quarter 2008 Results
11. SuperGen Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... September 30, 2014.  Biorem,s complete 2014 third quarter financial statements and ... Financial Summary:Three-months ended September 30, , Nine-months ended ... , 2014 , 2013 , 2014 ... 5,281 , 6,715 , 14,476 Gross profit ...
(Date:11/18/2014)... 2014 Athena Signature Series: Turning Cancer ‘Off’ ... Emerson, a professor in the Regulatory Biology Laboratory at the ... discovery points to an “off switch” for drug resistance in ... her local research is making a global impact in the ... then join host Cheryl K. Goodman, CEO of Social Global ...
(Date:11/18/2014)... Array Architects is proud of a 30-year ... nation's hospitals and health systems. It is a niche ... careers to the advancement of both the healthcare and ... field, Laura Silvoy has been chosen to share her ... Conference. , Laura will present her Process Simulation ...
(Date:11/17/2014)... The new METTLER TOLEDO White Paper ... challenges of becoming the first calibration laboratory in ... weights in the microgram range. National Metrology Institutes ... scientists involved in nanotechnology applications will benefit from ... calibration of weights in the range of 0.05 ...
Breaking Biology Technology:Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Array Healthcare Simulation Expert Slated to Speak at Winter Simulation Conference 2New White Paper on Microgram Weights Describes How to Achieve Traceable Measurement Down to 0.05 Milligrams 2
... Inc. (NASDAQ: NBIX ) today announced its financial results ... the third quarter of 2011, the Company reported net income of ... net income of $3.3 million, or $0.06 per fully diluted share ... ended September 30, 2011, the Company reported a net income of ...
... I: High Blood Pressure , aka Hypertension ... expensive, and mostly ineffective.   Fortunately , ... by natural methods that are both effective, inexpensive, and risk free. ... can help reduce   Chronic Heart/Cardiovascular Disease patients, ...
... Oct. 31, 2011 iBio, Inc. (NYSE ... issuance from the United States Patent and Trademark Office ... Genes in Plants," that further extends iBio,s patent coverage ... technology owned by iBio was developed by scientists at ...
Cached Biology Technology:Neurocrine Biosciences Reports Third Quarter 2011 Results 2Neurocrine Biosciences Reports Third Quarter 2011 Results 3Neurocrine Biosciences Reports Third Quarter 2011 Results 4Neurocrine Biosciences Reports Third Quarter 2011 Results 5Neurocrine Biosciences Reports Third Quarter 2011 Results 6Neurocrine Biosciences Reports Third Quarter 2011 Results 7Neurocrine Biosciences Reports Third Quarter 2011 Results 8Drug-Free BLOOD PRESSURE Control & Medical "Take-Away" Treatment are Potential Win-Win Solutions in Health Care 2iBio Announces New US Patent for iBioLaunch™ Technology 2iBio Announces New US Patent for iBioLaunch™ Technology 3
(Date:11/4/2014)... majority of Madagascar,s 101 species of lemurs are threatened ... the rainforests they call home. A new study by ... have on rainforest tree populations, which raises concerns about ... region,s rich biodiversity. , A large proportion of trees ... Lemurs in turn disperse the seeds of their fruit ...
(Date:11/3/2014)... , Nov. 3, 2014 Research and ... "Cell Therapy - Technologies, Markets and Companies" to ... cell therapy technologies and methods, which have already started to ... stem cell transplantation is replacing the old fashioned bone marrow ... Cell therapy is bound to become a part of medical ...
(Date:11/3/2014)... Nov. 3, 2014  NeuroSigma ® , Inc. ... sciences company focused on commercialization of its non-invasive ... the treatment of neurological and neuropsychiatric disorders, announced ... has issued a Notice of Allowance for Mexican ... co-owned by NeuroSigma and the Regents of the ...
Breaking Biology News(10 mins):Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... DCMay 28, 2008A 2008 American Society for Microbiology (ASM) ... to Marvin Whiteley, Assistant Professor, Molecular Genetics and Microbiology, ... Laboratories, the Merck Irving S. Sigal Memorial Award is ... instrumental in the early discovery of therapies to treat ...
... German . The sense of smell might ... fish or even mammals. This is the main conclusion of ... and her colleagues. The sense of smell in birds was, ... studies have shown that some bird species use their sense ...
... "Leatherback Turtle" you might think the sea turtles could stand ... them, and for more than a hundred million years, they ... of leatherbacks in the eastern Pacific Ocean has plummeted by ... many species that migrate across a vast ocean, pinpointing all ...
Cached Biology News:Do birds have a good sense of smell? 2Leatherback turtles' newly discovered migration route may be roadmap to salvation 2Leatherback turtles' newly discovered migration route may be roadmap to salvation 3Leatherback turtles' newly discovered migration route may be roadmap to salvation 4Leatherback turtles' newly discovered migration route may be roadmap to salvation 5Leatherback turtles' newly discovered migration route may be roadmap to salvation 6
Request Info...
... 5B15-5B-11E. Immunogen: Synthetic peptide derived from ... protein. Specificity: Specific for the ... Western blots it identifies the target band ... (positive controls: deglycosylated secreted media from primary ...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Biology Products: